1
|
Wang X, Ma Z, Wu Y, Chen J, Peng X, Wang Y, Fan M, Du J. Expression pattern of Ptch2 in mouse embryonic maxillofacial development. Acta Histochem 2022; 124:151835. [PMID: 34979374 DOI: 10.1016/j.acthis.2021.151835] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2021] [Revised: 11/26/2021] [Accepted: 12/17/2021] [Indexed: 01/17/2023]
Abstract
Embryogenesis is modulated by numerous complex signaling cascades, which are essential for normal development. The Hedgehog (Hh) signaling pathway is part of these central cascades. As a homolog of Patched (Ptch)-1, Ptch2 initially did not appear to be as important as Ptch1. Recent reports have revealed that Ptch2 plays a crucial role in ligand-dependent feedback inhibition of Hh signaling in vertebrates. The role of Ptch2 in facial development remains unclear. Here, we investigated the detailed expression pattern of Ptch2 during craniofacial development in murine embryos based on in situ hybridization (ISH) studies of whole-mounts and sections, immunohistochemistry (IHC), and quantitative real-time PCR. We found that both Ptch2 mRNA and protein expression increased in a dynamic pattern in the facial development at mouse embryonic days 11-14.5. Moreover, distinct expression of Ptch2 was observed in the structures of the facial region, such as the tooth germ, Meckel's cartilage, and the follicles of vibrissae. These data, combined with our work in the macrostomia family, suggest that Ptch2 may play a critical role in facial development.
Collapse
|
2
|
Park JE, Lee T, Ha K, Ki CS. Carrier frequency and incidence estimation of Smith-Lemli-Opitz syndrome in East Asian populations by Genome Aggregation Database (gnomAD) based analysis. Orphanet J Rare Dis 2021; 16:166. [PMID: 33836803 PMCID: PMC8033735 DOI: 10.1186/s13023-021-01789-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2021] [Accepted: 03/25/2021] [Indexed: 11/26/2022] Open
Abstract
Background Smith–Lemli–Opitz syndrome (SLOS) is an autosomal, recessively inherited congenital malformation syndrome characterized by multiple congenital anomalies such as microcephaly with mental defects, distinctive facial features, genital abnormalities, and 2–3 syndactyly of the toes. SLOS is caused by defective 7-dehydrocholesterol reductase, which is encoded by the DHCR7 gene. This study aimed to analyze the carrier frequency and expected incidence of SLOS in East Asians and Koreans using exome data from the Genome Aggregation Database (gnomAD) through the 2015 American College of Medical Genetics and Genomics and the Association for Molecular Pathology guideline (2015 ACMG-AMP guideline). Methods We analyzed 9197 exomes for East Asian populations from gnomAD, comprising 1909 Korean, 76 Japanese, and 7212 other East Asian populations. All identified variants were classified according to the 2015 ACMG-AMP guideline. Results According to the 2015 ACMG-AMP guideline, 15 pathogenic variant/likely pathogenic variant (PV/LPV) cases were identified in 33 East Asian individuals (33/9191 = 0.4%). Among them, four PVs/LPVs were identified in 19 Korean individuals (19/1909 = 1.0%). The predicted incidence, based upon the carrier rates of PV/LPV of DHCR7 alleles, is 1 in 310,688 in East Asians and l in 40,380 in Koreans. Conclusions This study is the first to identify carrier frequencies in East Asians and Koreans using gnomAD. It was confirmed that East Asians (0.4%) had a lower carrier frequency than did other ethnicities (1–3%) and Koreans (1.0%) had similar or lower carrier frequencies than other ethnicities. The variant spectrums of DHCR7 in East Asian and Korean populations differed greatly from those of other ethnic groups.
Collapse
Affiliation(s)
- Jong Eun Park
- Department of Laboratory Medicine, Hanyang University Guri Hospital, Hanyang University College of Medicine, Guri, Republic of Korea
| | - Taeheon Lee
- Green Cross Genome, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Republic of Korea
| | - Kyeongsu Ha
- Green Cross Genome, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Republic of Korea
| | - Chang-Seok Ki
- Green Cross Genome, 107, Ihyeon-ro 30beon-gil, Giheung-gu, Yongin-si, Gyeonggi-do, 16924, Republic of Korea.
| |
Collapse
|
3
|
Temple SEL, Sachdev R, Ellaway C. Familial DHCR7 genotype presenting as a very mild form of Smith-Lemli-Opitz syndrome and lethal holoprosencephaly. JIMD Rep 2020; 56:3-8. [PMID: 33204589 PMCID: PMC7653247 DOI: 10.1002/jmd2.12155] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/26/2020] [Revised: 07/15/2020] [Accepted: 07/17/2020] [Indexed: 11/09/2022] Open
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive metabolic disorder caused by variants in the DHCR7 gene. In cholesterol biosynthesis, 7-dehydrocholesterol (7-DHC) is converted to cholesterol by the enzyme 7-DHC reductase, which is encoded by the gene DHCR7. Thus, an elevated 7-DHC is indicative of SLOS. Characteristically SLOS is usually associated with congenital anomalies, dysmorphisms, and moderate to severe neurodevelopmental delay. However, there are rare descriptions of individuals with milder phenotypes. We report a mild case of SLOS presenting with short stature, cleft palate, imperforate anus, and mild language delay with subtle dysmorphic features. 7-DHC was not elevated at 1 year of age and SLOS considered excluded at this time. The parents had two pregnancies with holoprosencephaly. Whole exome sequencing of one of the fetuses identified compound heterozygous pathogenic variants in the DHCR7 gene (c.964-1G>C (p.?) and c.1039G>A (p.Gly347Ser) causative of SLOS. The proband with a mild form of SLOS was also found to have the same DHCR7 variants as the fetus and repeat testing of 7-DHC at 4 years of age was elevated, in keeping with SLOS. This case is the first to describe a wide intrafamilial phenotypic spectrum of SLOS as a result of the same DHCR7 genotype. This case also supports the findings of others that a normal or near normal development should not exclude SLOS. As demonstrated in this case exclusion of a metabolic diagnosis because of a negative biochemical marker such as 7-DHC is not absolute and if clinical suspicion remains genomic sequencing is warranted.
Collapse
Affiliation(s)
- Suzanna E. L. Temple
- Centre for Clinical GeneticsSydney Children's HospitalRandwickNew South WalesAustralia
| | - Rani Sachdev
- Centre for Clinical GeneticsSydney Children's HospitalRandwickNew South WalesAustralia
| | - Carolyn Ellaway
- Centre for Clinical GeneticsSydney Children's HospitalRandwickNew South WalesAustralia
| |
Collapse
|
4
|
Ramachandra Rao S, Pfeffer BA, Más Gómez N, Skelton LA, Keiko U, Sparrow JR, Rowsam AM, Mitchell CH, Fliesler SJ. Compromised phagosome maturation underlies RPE pathology in cell culture and whole animal models of Smith-Lemli-Opitz Syndrome. Autophagy 2018; 14:1796-1817. [PMID: 29979914 PMCID: PMC6135634 DOI: 10.1080/15548627.2018.1490851] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2017] [Revised: 05/25/2018] [Accepted: 06/11/2018] [Indexed: 12/27/2022] Open
Abstract
Treatment of rats with the cholesterol pathway inhibitor AY9944 produces an animal model of Smith-Lemli-Opitz syndrome (SLOS), an autosomal recessive disease caused by defective cholesterol synthesis. This SLOS rat model undergoes progressive and irreversible degeneration of the neural retina, with associated pathological features of the retinal pigmented epithelium (RPE). Here, we provide further insights into the mechanism involved in the RPE pathology. In the SLOS rat model, markedly increased RPE apical autofluorescence is observed, compared to untreated animals, which correlates with increased levels of A2E and other bisretinoids. Utilizing cultured human induced pluripotent stem cell (iPSC)- derived SLOS RPE cells, we found significantly elevated steady-state levels of 7-dehydrocholesterol (7DHC) and decreased cholesterol levels (key biochemical hallmarks of SLOS). Western blot analysis revealed altered levels of the macroautophagy/autophagy markers MAP1LC3B-II and SQSTM1/p62, and build-up of ubiquitinated proteins. Accumulation of immature autophagosomes was accompanied by inefficient degradation of phagocytized, exogenously supplied retinal rod outer segments (as evidenced by persistence of the C-terminal 1D4 epitope of RHO [rhodopsin]) in SLOS RPE compared to iPSC-derived normal human control. SLOS RPE cells exhibited lysosomal pH levels and CTSD activity within normal physiological limits, thus discounting the involvement of perturbed lysosomal function. Furthermore, 1D4-positive phagosomes that accumulated in the RPE in both pharmacological and genetic rodent models of SLOS failed to fuse with lysosomes. Taken together, these observations suggest that defective phagosome maturation underlies the observed RPE pathology. The potential relevance of these findings to SLOS and the requirement of cholesterol for phagosome maturation are discussed.
Collapse
Affiliation(s)
- Sriganesh Ramachandra Rao
- Departments of Ophthalmology (Ross Eye Institute) and Biochemistry, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA
- SUNY Eye Institute, Buffalo, NY, USA
- Research Service, VA Western NY Healthcare System, Buffalo, NY, USA
| | - Bruce A. Pfeffer
- Departments of Ophthalmology (Ross Eye Institute) and Biochemistry, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA
- SUNY Eye Institute, Buffalo, NY, USA
- Research Service, VA Western NY Healthcare System, Buffalo, NY, USA
| | - Néstor Más Gómez
- Department of Anatomy & Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA, USA
| | - Lara A. Skelton
- Departments of Ophthalmology (Ross Eye Institute) and Biochemistry, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA
- SUNY Eye Institute, Buffalo, NY, USA
- Research Service, VA Western NY Healthcare System, Buffalo, NY, USA
| | - Ueda Keiko
- Departments of Ophthalmology (Harkness Eye Institute) and Pathology & Cell Biology, Columbia University, College of Physicians & Surgeons, NY, NY, USA
| | - Janet R. Sparrow
- Departments of Ophthalmology (Harkness Eye Institute) and Pathology & Cell Biology, Columbia University, College of Physicians & Surgeons, NY, NY, USA
| | - Aryn M. Rowsam
- Departments of Ophthalmology (Ross Eye Institute) and Biochemistry, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA
- SUNY Eye Institute, Buffalo, NY, USA
- Research Service, VA Western NY Healthcare System, Buffalo, NY, USA
| | - Claire H. Mitchell
- Department of Anatomy & Cell Biology, University of Pennsylvania, School of Dental Medicine, Philadelphia, PA, USA
| | - Steven J. Fliesler
- Departments of Ophthalmology (Ross Eye Institute) and Biochemistry, Jacobs School of Medicine and Biomedical Sciences, SUNY-University at Buffalo, Buffalo, NY, USA
- SUNY Eye Institute, Buffalo, NY, USA
- Research Service, VA Western NY Healthcare System, Buffalo, NY, USA
| |
Collapse
|
5
|
Peng Y, Myers R, Zhang W, Alexov E. Computational Investigation of the Missense Mutations in DHCR7 Gene Associated with Smith-Lemli-Opitz Syndrome. Int J Mol Sci 2018; 19:E141. [PMID: 29300326 PMCID: PMC5796090 DOI: 10.3390/ijms19010141] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 12/29/2017] [Accepted: 12/30/2017] [Indexed: 12/25/2022] Open
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is a cholesterol synthesis disorder characterized by physical, mental, and behavioral symptoms. It is caused by mutations in 7-dehydroxycholesterolreductase gene (DHCR7) encoding DHCR7 protein, which is the rate-limiting enzyme in the cholesterol synthesis pathway. Here we demonstrate that pathogenic mutations in DHCR7 protein are located either within the transmembrane region or are near the ligand-binding site, and are highly conserved among species. In contrast, non-pathogenic mutations observed in the general population are located outside the transmembrane region and have different effects on the conformational dynamics of DHCR7. All together, these observations suggest that the non-classified mutation R228Q is pathogenic. Our analyses indicate that pathogenic effects may affect protein stability and dynamics and alter the binding affinity and flexibility of the binding site.
Collapse
Affiliation(s)
- Yunhui Peng
- Department of Physics and Astronomy, Clemson University, Clemson, SC 29630, USA.
| | - Rebecca Myers
- Department of Healthcare Genetics, Clemson University, Clemson, SC 29630, USA.
| | - Wenxing Zhang
- Department of Chemistry, Clemson University, Clemson, SC 29630, USA.
| | - Emil Alexov
- Department of Physics and Astronomy, Clemson University, Clemson, SC 29630, USA.
| |
Collapse
|
6
|
Lazarin GA, Haque IS, Evans EA, Goldberg JD. Smith-Lemli-Opitz syndrome carrier frequency and estimates of in utero mortality rates. Prenat Diagn 2017; 37:350-355. [PMID: 28166604 PMCID: PMC5413855 DOI: 10.1002/pd.5018] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2016] [Revised: 01/23/2017] [Accepted: 01/25/2017] [Indexed: 12/19/2022]
Abstract
Objective To tabulate individual allele frequencies and total carrier frequency for Smith–Lemli–Opitz syndrome (SLOS) and compare expected versus observed birth incidences. Methods A total of 262 399 individuals with no known indication or increased probability of SLOS carrier status, primarily US based, were screened for SLOS mutations as part of an expanded carrier screening panel. Results were retrospectively analyzed to estimate carrier frequencies in multiple ethnic groups. SLOS birth incidences obtained from existing literature were then compared with these data to estimate the effect of SLOS on fetal survival. Results Smith–Lemli–Opitz syndrome carrier frequency is highest in Ashkenazi Jews (1 in 43) and Northern Europeans (1 in 54). Comparing predicted birth incidence with that observed in published literature suggests that approximately 42% to 88% of affected conceptuses experience prenatal demise. Conclusion Smith–Lemli–Opitz syndrome is relatively frequent in certain populations and, because of its impact on prenatal and postnatal morbidity and mortality, merits consideration for routine screening. © 2017 The Authors. Prenatal Diagnosis published by John Wiley & Sons, Ltd. What's already known about this topic?
Smith–Lemli–Opitz syndrome is an autosomal recessive multiple congenital anomaly syndrome with varying frequency estimates. Smith–Lemli–Opitz syndrome is presumed to be associated with an increased risk for pregnancy loss, although this risk has not been quantified.
What does this study add?
By reporting results from a large, diverse tested population, these data define the carrier frequency in multiple ethnic groups. Predicted Smith–Lemli–Opitz syndrome frequency at birth is compared with actual frequencies from previous studies, enabling estimation of the pregnancy loss frequency.
Collapse
|
7
|
Blassberg R, Macrae JI, Briscoe J, Jacob J. Reduced cholesterol levels impair Smoothened activation in Smith-Lemli-Opitz syndrome. Hum Mol Genet 2015; 25:693-705. [PMID: 26685159 PMCID: PMC4743690 DOI: 10.1093/hmg/ddv507] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2015] [Accepted: 12/08/2015] [Indexed: 12/21/2022] Open
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is a common autosomal-recessive disorder that results from mutations in the gene encoding the cholesterol biosynthetic enzyme 7-dehydrocholesterol reductase (DHCR7). Impaired DHCR7 function is associated with a spectrum of congenital malformations, intellectual impairment, epileptiform activity and autism spectrum disorder. Biochemically, there is a deficit in cholesterol and an accumulation of its metabolic precursor 7-dehydrocholesterol (7DHC) in developing tissues. Morphological abnormalities in SLOS resemble those seen in congenital Sonic Hedgehog (SHH)-deficient conditions, leading to the proposal that the pathogenesis of SLOS is mediated by aberrant SHH signalling. SHH signalling is transduced through the transmembrane protein Smoothened (SMO), which localizes to the primary cilium of a cell on activation and is both positively and negatively regulated by sterol molecules derived from cholesterol biosynthesis. One proposed mechanism of SLOS involves SMO dysregulation by altered sterol levels, but the salient sterol species has not been identified. Here, we clarify the relationship between disrupted cholesterol metabolism and reduced SHH signalling in SLOS by modelling the disorder in vitro. Our results indicate that a deficit in cholesterol, as opposed to an accumulation of 7DHC, impairs SMO activation and its localization to the primary cilium.
Collapse
Affiliation(s)
- Robert Blassberg
- The Francis Crick Institute, Mill Hill Laboratory, Mill Hill, London NW7 1AA, UK
| | - James I Macrae
- The Francis Crick Institute, Mill Hill Laboratory, Mill Hill, London NW7 1AA, UK
| | - James Briscoe
- The Francis Crick Institute, Mill Hill Laboratory, Mill Hill, London NW7 1AA, UK
| | - John Jacob
- Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, Level 6, West Wing, Oxford OX3 9DU, UK, Department of Neurology, Milton Keynes Hospital, Standing Way, Milton Keynes, Buckinghamshire MK6 5LD, UK and Department of Neurology, John Radcliffe Hospital, Headley Way, Oxford OX3 9DU, UK
| |
Collapse
|
8
|
Abstract
Brain malformations, particularly related to early brain development, are a clinically and genetically heterogeneous group of fetal neurological disorders. Fetal cerebral malformation, predominantly of impaired prosencephalic development namely agenesis of the corpus callosum and septo-optic dysplasia, is the main pathological feature in fetus, and causes prominent neurodevelopmental retardation, and associated with congenital facial anomalies and visual disorders. Differential diagnosis of brain malformations can be extremely difficult even through magnetic resonance imaging. Advances in genomic and molecular genetics technologies have led to the identification of the sonic hedgehog pathways and genes critical to the normal brain development. Molecular cytogenetic and genetic studies have identified numeric and structural chromosomal abnormalities as well as mutations in genes important for the etiology of fetal neurological disorders. In this review, we update the molecular genetics findings of three common fetal neurological abnormalities, holoprosencephaly, lissencephaly and agenesis of the corpus callosum, in an attempt to assist in perinatal and prenatal diagnosis.
Collapse
Affiliation(s)
- Jin Huang
- Fetal Medicine Unit, Department of Obstetrics and Gynaecology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR
| | | | | | | |
Collapse
|
9
|
Nowaczyk MJM, Irons MB. Smith-Lemli-Opitz syndrome: phenotype, natural history, and epidemiology. AMERICAN JOURNAL OF MEDICAL GENETICS PART C-SEMINARS IN MEDICAL GENETICS 2012; 160C:250-62. [PMID: 23059950 DOI: 10.1002/ajmg.c.31343] [Citation(s) in RCA: 93] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is a congenital multiple anomaly/intellectual disability syndrome caused by a deficiency of cholesterol synthesis resulting from a deficiency of 7-dehydrocholesterol (7DHC) reductase encoded by DHCR7. SLOS is inherited in an autosomal recessive pattern. It is characterized by prenatal and postnatal growth retardation, microcephaly, a variable degree of intellectual disability that encompasses normal intelligence to severe intellectual deficiency, and multiple major and minor malformations. External malformations include distinctive facial features, cleft palate, postaxial polydactyly, 2-3 syndactyly of the toes, and underdeveloped external genitalia in males, while internal anomalies may affect every organ system. The clinical spectrum is wide, and rare individuals have been described with normal development and only minor malformations. The clinical diagnosis of SLOS is confirmed by demonstrating an abnormally elevated concentration of the cholesterol precursor, 7DHC, in serum or other tissues, or by the presence of two DHCR7 mutations. The enzymatic deficiency results in decreased cholesterol and increased 7DHC levels, both during embryonic development and after birth. The malformations found in SLOS may result from decreased cholesterol, increased 7DHC or a combination of these two factors. This review discusses the physical and behavioral phenotype of SLOS, the diagnostic approaches, the natural history from the prenatal period to adulthood, and current understanding of the pathophysiology of SLOS.
Collapse
Affiliation(s)
- Małgorzata J M Nowaczyk
- Department of Pathology and Molecular Medicine and Department of Pediatrics, McMaster University McMaster University Medical Centre, Room 3N16, 1200 Main Street West, Hamilton ON, Canada L8S 4J9.
| | | |
Collapse
|
10
|
Abstract
In vertebrate hedgehog signaling, hedgehog ligands are processed to become bilipidated and then multimerize, which allows them to leave the signaling cell via Dispatched 1 and become transported via glypicans and megalin to the responding cells. Hedgehog then interacts with a complex of Patched 1 and Cdo/Boc, which activates endocytic Smoothened to the cilium. Patched 1 regulates the activity of Smoothened (1) via Vitamin D3, which inhibits Smoothened in the absence of hedgehog ligand or (2) via oxysterols, which activate Smoothened in the presence of hedgehog ligand. Hedgehog ligands also interact with Hip1, Patched 2, and Gas1, which regulate the range as well as the level of hedgehog signaling. In vertebrates, Smoothened is shortened at its C-terminal end and lacks most of the phosphorylation sites of importance in Drosophila. Cos2, also of importance in Drosophila, plays no role in mammalian transduction, nor do its homologs Kif7 and Kif27. The cilium may provide a function analogous to that of Cos2 by linking Smoothened to the modulation of Gli transcription factors. Disorders associated with the hedgehog signaling network follow, including nevoid basal cell carcinoma syndrome, holoprosencephaly, Smith-Lemli-Opitz syndrome, Greig cephalopolysyndactyly syndrome, Pallister-Hall syndrome, Carpenter syndrome, and Rubinstein-Taybi syndrome.
Collapse
Affiliation(s)
- M Michael Cohen
- Department of Pediatrics, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
| |
Collapse
|
11
|
Solcà C, Pandit B, Yu H, Tint GS, Patel SB. Loss of apolipoprotein E exacerbates the neonatal lethality of the Smith-Lemli-Opitz syndrome mouse. Mol Genet Metab 2007; 91:7-14. [PMID: 17197219 PMCID: PMC1852500 DOI: 10.1016/j.ymgme.2006.11.009] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/17/2006] [Accepted: 11/17/2006] [Indexed: 11/19/2022]
Abstract
The Smith-Lemli-Opitz syndrome (SLOS) is caused by a genetic defect in cholesterol biosynthesis; mutations in the enzyme 3ss-hydroxysterol Delta7 reductase (Dhcr7) lead to a failure of cholesterol (and desmosterol) synthesis, with an accumulation of precursor sterols, such as 7-dehydrocholesterol. Extensive genotype-phenotype analyses have indicated that there is considerable variation in the severity of the disease, much of which is not explained by defects in the Dhcr7 gene alone. Factors ranging from variations in maternal-fetal cholesterol transfer during pregnancy, to other genetic factors have been proposed to account for this variability. Variations at the APOE locus affect plasma cholesterol levels in humans and this polymorphic gene has been found to be associated with cardiovascular as well as neurological disorders. This locus has recently been implicated in accounting for some of the variations in SLOS. To address whether maternal hypercholesterolemia can affect fetal outcome, we tested the ability of maternal hypercholesterolemia to rescue the neonatal lethality in a mouse model of SLOS. Maternal hypercholesterolemia, induced by ApoE or Ldl-r deficiency not only failed to ameliorate the postnatal lethality, it increased the prenatal mortality of Dhcr7 deficient pups. Thus the murine data suggest that maternal loss of ApoE or Ldl-r function further exacerbates the neonatal lethality, suggesting they may play a role in maternal transfer of cholesterol to the embryo.
Collapse
Affiliation(s)
- Curzio Solcà
- Division of Endocrinology, Metabolism and Clinical Nutrition, Medical College of Wisconsin, Milwaukee, WI 53226, USA
| | | | | | | | | |
Collapse
|
12
|
Scalco FB, Otto PA, Brunetti IL, Cruzes VM, Moretti-Ferreira D. Smith-Lemli-Opitz syndrome: clinical and biochemical findings in Brazilian patients. Genet Mol Biol 2006. [DOI: 10.1590/s1415-47572006000300003] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
|
13
|
Nowaczyk MJM, Waye JS, Douketis JD. DHCR7 mutation carrier rates and prevalence of the RSH/Smith-Lemli-Opitz syndrome: Where are the patients? Am J Med Genet A 2006; 140:2057-62. [PMID: 16906538 DOI: 10.1002/ajmg.a.31413] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
RSH/Smith-Lemli-Opitz (SLOS) is an inborn error of metabolism with protean manifestations. Its exact incidence and prevalence are not known; however, the carrier rate for the most frequently occurring mutation, the null mutation IVS8-1G > C, is approximately 1 in 100 for the Caucasian population in North America (1%) and possibly as high as 1 in 50 to 1 in 30 in Central European populations (2-3.3%). Based on the allele frequencies and the proportion of this mutation observed in various patient populations, the expected incidence of RSH/SLOS in those populations was calculated and reported to be between 1 in 1,590 and 1 in 17,000. However, around the world the observed prevalence and incidence are much lower than those calculated from the individual mutation carrier rates observed in any given population. The discrepancy between the expected incidence and prevalence can be explained only in part by the neonatal and infancy deaths of the most severely affected children with RSH/SLOS and the under ascertainment of mild and atypical cases at the mild end of the spectrum. RSH/SLOS may be responsible for a high number of miscarriages. Recent observations estimate the prevalence of SLOS at 16 weeks of gestation as similar to that observed at birth (approximately 1 in 60,000) suggesting that either reduced fertility of carrier couples or losses of affected embryos or fetuses in the first trimester play a significant role in reducing the second trimester prevalence of RSH/SLOS. It is possible that the estimates of carrier rates based on population screening for the most commonly occurring mutations may not reflect the true carrier rates in the population. In order to reconcile the above-mentioned paradoxes, we propose a model based on a higher than observed carrier frequency of the most common mutation and on very high fetal loss of homozygotes for that mutation.
Collapse
|
14
|
Anstey AV, Azurdia RM, Rhodes LE, Pearse AD, Bowden PE. Photosensitive Smith-Lemli-Opitz syndrome is not caused by a single gene mutation: analysis of the gene encoding 7-dehydrocholesterol reductase in five U.K. families. Br J Dermatol 2005; 153:774-9. [PMID: 16181459 DOI: 10.1111/j.1365-2133.2005.06761.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive malformation syndrome characterized by a disorder in cholesterol metabolism. SLOS is caused by mutations in the DHCR7 gene which encodes 7-dehydrocholesterol reductase, an enzyme that catalyses the final step in cholesterol biosynthesis. We have previously established the clinical and photobiological features of the photosensitivity that is frequently a feature of SLOS. OBJECTIVES In this study, we have performed mutational analysis of the DHCR7 gene in individuals from five families with SLOS. In each family, one member was affected by severe photosensitivity as a manifestation of SLOS. METHODS Fifteen samples (including family controls) were screened using polymerase chain reaction amplification and direct automated sequencing. RESULTS Six different DHCR7 mutations were identified of which five were single point mutations that caused missense amino acid substitutions (P51H, T93M, L99P, E448K and R450L). The other was a splice site mutation (G-->C in splice acceptor site) affecting the intron 8-exon 9 splice junction (IVS8-1 G-->C). This splice site mutation and four of the five missense mutations have been previously published as causal in SLOS but the P51H is a novel mutation which has not previously been reported. CONCLUSIONS This is the first study in which DHCR7 gene mutational analysis has been performed on SLOS subjects with severe photosensitivity and indicates that no single mutation is responsible for the photosensitivity which characterizes this disorder.
Collapse
Affiliation(s)
- A V Anstey
- Department of Dermatology, Royal Liverpool University Hospital, Liverpool L7 8XP, U.K
| | | | | | | | | |
Collapse
|
15
|
Matsumoto Y, Morishima KI, Honda A, Watabe S, Yamamoto M, Hara M, Hasui M, Saito C, Takayanagi T, Yamanaka T, Saito N, Kudo H, Okamoto N, Tsukahara M, Matsuura S. R352Q mutation of the DHCR7 gene is common among Japanese Smith-Lemli-Opitz syndrome patients. J Hum Genet 2005; 50:353-356. [PMID: 16044199 DOI: 10.1007/s10038-005-0267-3] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2005] [Accepted: 06/06/2005] [Indexed: 10/25/2022]
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive malformation syndrome characterized by microcephaly, syndactyly of toes, ambiguous genitalia, and mental retardation. The underlying DHCR7 gene has been identified and a wide variety of distinct mutations were reported in USA and European SLOS patients. A significant difference has been suggested in the frequency of SLOS among different ethnic populations. Here, we report mutational analysis of seven Japanese SLOS patients. Five mutations, R352Q, R242H, G303R, X476Q, and S192F, were identified, and R352Q appeared most frequent, since nine out of the 13 mutations of Japanese origin were the same R352Q. These results suggest that R352Q is a predominant founder mutation in Japanese SLOS patients.
Collapse
Affiliation(s)
- Yoshiyuki Matsumoto
- Department of Radiation Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Ken-Ichi Morishima
- Department of Radiation Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan
| | - Akira Honda
- Department of Gastroenterology, University of Tsukuba, Tsukuba, Japan
| | - Shoji Watabe
- Faculty of Health Sciences, Yamaguchi University School of Medicine, Ube, Japan
| | - Misa Yamamoto
- Faculty of Health Sciences, Yamaguchi University School of Medicine, Ube, Japan
| | - Masayuki Hara
- General Isotope Center, Tokyo Medical and Dental University, Tokyo, Japan
| | | | - Chikako Saito
- Department of Psychiatrics, National Sanatorium Hokuriku Hospital, Joe-hana, Japan
| | | | - Tsutomu Yamanaka
- Department of Human Welfare, Okazaki Women's Junior College, Okazaki, Japan
| | | | - Hideaki Kudo
- Asahigawasou Ryoiku Center Ryoikuen, Okayama, Japan
| | - Nobuhiko Okamoto
- Osaka Medical Center and Research Institute for Maternal and Child Health, Osaka, Japan
| | - Masato Tsukahara
- Faculty of Health Sciences, Yamaguchi University School of Medicine, Ube, Japan
| | - Shinya Matsuura
- Department of Radiation Biology, Research Institute for Radiation Biology and Medicine, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima 734-8553, Japan.
| |
Collapse
|
16
|
Cardoso ML, Balreira A, Martins E, Nunes L, Cabral A, Marques M, Lima MR, Marques JS, Medeira A, Cordeiro I, Pedro S, Mota MC, Dionisi-Vici C, Santorelli FM, Jakobs C, Clayton PT, Vilarinho L. Molecular studies in Portuguese patients with Smith-Lemli-Opitz syndrome and report of three new mutations in DHCR7. Mol Genet Metab 2005; 85:228-35. [PMID: 15979035 DOI: 10.1016/j.ymgme.2005.02.009] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2005] [Revised: 02/16/2005] [Accepted: 02/16/2005] [Indexed: 10/25/2022]
Abstract
Smith-Lemli-Opitz syndrome (SLO) is an autosomal recessive disorder characterised by craniofacial dysmorphism, mental retardation, multiple congenital anomalies, and increased levels of 7-dehydrocholesterol (7-DHC) in body tissues and fluids. SLO is caused by mutations in the DHCR7 gene which encodes 7-dehydrocholesterol reductase, the last enzyme of cholesterol biosynthesis pathway. In our investigation, we screened 682 dysmorphic/mentally retarded Portuguese patients for abnormal levels of 7-DHC in blood by UV spectrometry. We identified six unrelated patients with SLO (0.87% of total). Mutational analysis of the DHCR7 gene led to the identification of seven distinct mutations, three of which are new (F174S, H301R, and Q98X). The common IVS8-1G > C and T93M variants together with the H301R accounted for 70% of the all SLO alleles in our population. Our findings contribute to the variegate array of pathological changes in the DHCR7 gene among different European populations.
Collapse
Affiliation(s)
- M L Cardoso
- Instituto de Genética Médica Jacinto de Magalhães, Oporto, Portugal
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Correa-Cerro LS, Porter FD. 3beta-hydroxysterol Delta7-reductase and the Smith-Lemli-Opitz syndrome. Mol Genet Metab 2005; 84:112-26. [PMID: 15670717 DOI: 10.1016/j.ymgme.2004.09.017] [Citation(s) in RCA: 57] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/02/2004] [Revised: 09/28/2004] [Accepted: 09/28/2004] [Indexed: 10/26/2022]
Abstract
In the final step of cholesterol synthesis, 7-dehydrocholesterol reductase (DHCR7) reduces the double bond at C7-8 of 7-dehydrocholesterol to yield cholesterol. Mutations of DHCR7 cause Smith-Lemli-Opitz syndrome (SLOS). Over 100 different mutations of DHCR7 have been identified in SLOS patients. SLOS is a classical multiple malformation, mental retardation syndrome, and was the first human malformation syndrome shown to result from an inborn error of cholesterol synthesis. This paper reviews the biochemical, molecular, and mutational aspects of DHCR7.
Collapse
Affiliation(s)
- Lina S Correa-Cerro
- Unit on Molecular Dysmorphology, Heritable Disorders Branch, Department of Health and Human Services, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA
| | | |
Collapse
|
18
|
Abstract
OBJECTIVES To determine the incidence and point prevalence of Smith-Lemli-Opitz syndrome (SLOS) in Canada; to determine the percentage of mild cases of SLOS; and to determine the age of diagnosis of mildly affected patients. SLOS is a treatable genetic condition that may be difficult to diagnose in its mildest form because of nonspecific clinical markers (two- to three-toe webbing, short upturned nose, and micrognathia). STUDY DESIGN More than 2000 Canadian pediatricians and pediatric specialists were surveyed monthly for 36 months through a standing national surveillance program. A clinical identification form was designed to identify patients with SLOS or its phenocopies. Clinical information was obtained on all reported cases; suggested cases were investigated by biochemical or molecular analysis. RESULTS Thirty-five of 86 reports of suggested SLOS were confirmed SLOS. Twelve infants with SLOS were born during the surveillance period, and two additional infants with SLOS were diagnosed prenatally. Twenty-one infants with SLOS were born before the onset of surveillance. CONCLUSIONS The minimum incidence of SLOS in Canada is 1 in 70,358 live births. The minimum prevalence of SLOS is approximately 1 in 950,000. Eighteen percent of patients were mildly affected; the mean age of diagnosis of mildly affected patients was 5.3 years.
Collapse
|
19
|
Shim YH, Bae SH, Kim JH, Kim KR, Kim CJ, Paik YK. A novel mutation of the human 7-dehydrocholesterol reductase gene reduces enzyme activity in patients with holoprosencephaly. Biochem Biophys Res Commun 2004; 315:219-23. [PMID: 15013448 DOI: 10.1016/j.bbrc.2004.01.041] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2003] [Indexed: 11/30/2022]
Abstract
Defects in cholesterol biosynthesis genes are recognized as a leading cause for holoprosencephaly (HPE). Previous reports suggest that mutations of human 7-dehydrocholesterol reductase (Dhcr7), which catalyzes the final step of cholesterol biosynthesis, may cause HPE [Clin. Genet. 53 (1998) 155]. To determine whether Dhcr7 mutations are involved in HPE pathogenesis, we analyzed the sequence of exon 9, which contains both a catalytic domain and a mutational hot spot. We examined 36 prematurely terminated fetuses with HPE at their gestation ages in the range from 21 to 33 weeks by single strand conformation polymorphism analysis and DNA sequencing. A novel missense mutation was identified: G344D. Dhcr7 enzyme assays using overexpressed recombinant mutant proteins revealed altered enzyme activity. Mutant G344D harbored less than 50% of enzyme activity compared with the control. Two previously reported mutations, R404C and G410S, abolished enzyme activity. These results suggest that mutation of the Dhcr7 gene is involved in HPE pathogenesis.
Collapse
Affiliation(s)
- Yhong-Hee Shim
- Department of Biological Sciences and Bio/Molecular Informatics Center, Konkuk University, Seoul 143-701, Republic of Korea.
| | | | | | | | | | | |
Collapse
|
20
|
Lalovic A, Sequeira A, DeGuzman R, Chawky N, Lesage A, Seguin M, Turecki G. Investigation of completed suicide and genes involved in cholesterol metabolism. J Affect Disord 2004; 79:25-32. [PMID: 15023477 DOI: 10.1016/s0165-0327(02)00453-6] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2002] [Accepted: 11/22/2002] [Indexed: 11/25/2022]
Abstract
BACKGROUND Several lines of evidence support the association between low or lowered levels of serum total cholesterol and suicide. Genetic epidemiological studies suggest that genes predispose to suicide. Given that genes control many aspects of cholesterol biosynthesis and metabolism, one approach through which to explore the putative association between low cholesterol and suicide is through genetic studies. METHODS We examined the potential role of five genes encoding proteins involved in cholesterol biosynthesis and transport in a total sample of 305 male Caucasian subjects, consisting of 145 suicide completers and 160 controls. We investigated variation in the HMG CoA reductase (HMGCR), 7-dehydrocholesterol reductase (DHCR7), lipoprotein lipase (LPL), low-density lipoprotein receptor (LDLR), and apolipoprotein E (APOE) genes. RESULTS We were unable to detect significant differences in allele or genotype frequencies between the suicide cases and controls for any of the genes studied. No relationship was found between genotype and impulsivity or aggression as measured using the BIS and BDHI, respectively. LIMITATIONS The limitations of this study are consistent with the typical limitations inherent in most genetic association studies involving complex behavioral traits. CONCLUSION Although these genes are unlikely to play a major role in susceptibility to suicide, further studies in a larger sample are necessary to reveal the smaller genetic effects, if present.
Collapse
Affiliation(s)
- Aleksandra Lalovic
- McGill Group for Suicide Studies, Douglas Hospital Research Centre, 6875 LaSalle Blvd., Verdun, Québec, Canada H4H 1R3
| | | | | | | | | | | | | |
Collapse
|
21
|
Wright BS, Nwokoro NA, Wassif CA, Porter FD, Waye JS, Eng B, Nowaczyk MJM. Carrier frequency of the RSH/Smith-Lemli-Opitz IVS8-1G>C mutation in African Americans. Am J Med Genet A 2003; 120A:139-41. [PMID: 12794707 DOI: 10.1002/ajmg.a.10207] [Citation(s) in RCA: 19] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
22
|
Jira PE, Waterham HR, Wanders RJA, Smeitink JAM, Sengers RCA, Wevers RA. Smith-Lemli-Opitz syndrome and the DHCR7 gene. Ann Hum Genet 2003; 67:269-80. [PMID: 12914579 DOI: 10.1046/j.1469-1809.2003.00034.x] [Citation(s) in RCA: 53] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Smith-Lemli-Opitz syndrome, a severe developmental disorder associated with multiple congenital anomalies, is caused by a defect of cholesterol biosynthesis. Low cholesterol and high concentrations of its direct precursor, 7-dehydrocholesterol, in plasma and tissues are the diagnostic biochemical hallmarks of the syndrome. The plasma sterol concentrations correlate with severity and disease outcome. Mutations in the DHCR7 gene lead to deficient activity of 7-dehydrocholesterol reductase (DHCR7), the final enzyme of the cholesterol biosynthetic pathway. The human DHCR7 gene is localised on chromosome 11q13 and its structure has been characterized. Ninety-one different mutations in the DHCR7 gene have been published to date. This paper is a review of the clinical, biochemical and molecular genetic aspects.
Collapse
Affiliation(s)
- P E Jira
- Department of Pediatrics, University Medical Centre Nijmegen, 6500 HB Nijmegen, the Netherlands
| | | | | | | | | | | |
Collapse
|
23
|
Patrono C, Dionisi-Vici C, Giannotti A, Bembi B, Digilio MC, Rizzo C, Purificato C, Martini C, Pierini R, Santorelli FM. Two novel mutations of the human Δ7-sterol reductase (DHCR7) gene in children with Smith–Lemli–Opitz syndrome. Mol Cell Probes 2002; 16:315-8. [PMID: 12270273 DOI: 10.1006/mcpr.2002.0426] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
We analyzed seven unrelated children with the Smith-Lemli-Opitz syndrome (SLOS) for mutations in the delta7-sterol reductase gene by using SSCP and direct sequencing. We identified two novel mutations (V330M and R363C) in the DHCR7 gene. Reported mutations found in this study were T93M (3/14 alleles), E448K (2/14), and W151X, G244R, P329L, and R446Q (each found in one allele). The so-called common IVS8-1 G --> C was found in three alleles, confirming its relative rarity among Italian SLOS families. By using a scoring system, clinical severity did not seem to correlate with 7DHC levels and type of mutation. Expanding the spectrum of mutations in SLOS, our study does not support direct genotype-phenotype correlation.
Collapse
Affiliation(s)
- C Patrono
- Molecular Medicine, Metabolism, and Genetics, IRCCS - Children's Hospital Bambino Gesù, Rome, Italy
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Xiong Q, Ruan B, Whitby FG, Tuohy RP, Belanger TL, Kelley RI, Wilson WK, Schroepfer GJ. A colorimetric assay for 7-dehydrocholesterol with potential application to screening for Smith-Lemli-Opitz syndrome. Chem Phys Lipids 2002; 115:1-15. [PMID: 12047895 DOI: 10.1016/s0009-3084(01)00205-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Smith-Lemli-Opitz syndrome (SLOS; MIM 270400) is a genetic disorder characterized by hypocholesterolemia and elevated 7-dehydrocholesterol (7DHC) levels resulting from mutations affecting 7-dehydrocholesterol reductase. We describe a colorimetric assay for 7DHC with potential application to large-scale screening for SLOS. Reaction of 7DHC and its esters with the Liebermann-Burchard reagent resulted in a brief initial absorbance at 510 nm (pink color) followed by an absorbance at 620 nm (blue color) after 2 min, while cholesterol samples were essentially colorless. The assay could identify typical SLOS blood samples by their pink color and increased absorbance at 620 nm after 2 min. Colorimetric identification of mild SLOS cases requires monitoring of the transient absorbance at 510 nm, which must be detected immediately after rapid, consistent mixing of the reagents. The need for special mixing devices and rigorous validation precludes sporadic use of the assay for diagnosing suspected SLOS cases. We also studied the stability of 7DHC in dried SLOS blood spots on Guthrie cards, which are widely used for archiving neonatal blood. Decomposition of 7DHC was effectively retarded by storage at low temperature and by precoating of the cards with antioxidants. The combined results provide a foundation for development of a simple, automated test for SLOS screening.
Collapse
Affiliation(s)
- Quanbo Xiong
- Department of Biochemistry and Cell Biology, Rice University, MS140, 6100 Main Street, Houston, TX 77005-1892, USA
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Has C, Seedorf U, Kannenberg F, Bruckner-Tuderman L, Folkers E, Fölster-Holst R, Baric I, Traupe H. Gas chromatography-mass spectrometry and molecular genetic studies in families with the Conradi-Hünermann-Happle syndrome. J Invest Dermatol 2002; 118:851-8. [PMID: 11982764 DOI: 10.1046/j.1523-1747.2002.01761.x] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The Conradi-Hünermann-Happle syndrome is an X-linked dominant disease that is due to mutations in the gene for emopamil binding protein. Emopamil binding protein is a Delta8-Delta7 sterol isomerase and plays a pivotal role in the final steps of cholesterol biosynthesis. We wanted to know to what extent this X-linked dominant enzyme defect has functional consequences at the biochemical level and whether it is possible to predict the clinical phenotype from serum sterol measurements. Therefore we performed sterol biochemical studies in 11 Conradi-Hünermann-Happle syndrome families and compared the results obtained to the clinical and molecular genetic findings. To assess disease severity a score considering bone and skin involvement and further features was used. For evaluation of the functional consequences we studied serum samples using gas chromatography-mass spectrometry analysis. For mutation screening we analyzed the emopamil binding protein gene using polymerase chain reaction, heteroduplex analysis of all exons, direct sequencing, and restriction enzyme analysis. Mutations in the emopamil binding protein gene were found in all 11 families including seven novel mutations affecting exons 2, 4, and 5. Gas chromatography-mass spectrometry analysis revealed markedly elevated levels of 8-dehydrocholesterol and of cholest-8(9)-en-3beta-ol and helped to identify somatic mosaicism in a clinically unaffected man. The extent of the metabolic alterations in the serum, however, do not allow prediction of the clinical phenotype, nor the genotype. This lack of correlation may be due to differences in X-inactivation between different tissues of the same patient and/or loss of the mutant clone by outgrowth of proficient clones after some time.
Collapse
Affiliation(s)
- Cristina Has
- Department of Dermatology, University Hospital Muenster, Germany.
| | | | | | | | | | | | | | | |
Collapse
|
26
|
Abstract
The known disorders of cholesterol biosynthesis have expanded rapidly since the discovery that Smith-Lemli-Opitz syndrome is caused by a deficiency of 7-dehydrocholesterol. Each of the six now recognized sterol disorders-mevalonic aciduria, Smith-Lemli-Opitz syndrome, desmosterolosis, Conradi-Hünermann syndrome, CHILD syndrome, and Greenberg dysplasia-has added to our knowledge of the relationship between cholesterol metabolism and embryogenesis. One of the most important lessons learned from the study of these disorders is that abnormal cholesterol metabolism impairs the function of the hedgehog class of embryonic signaling proteins, which help execute the vertebrate body plan during the earliest weeks of gestation. The study of the enzymes and genes in these several syndromes has also expanded and better delineated an important class of enzymes and proteins with diverse structural functions and metabolic actions that include sterol biosynthesis, nuclear transcriptional signaling, regulation of meiosis, and even behavioral modulation.
Collapse
Affiliation(s)
- R I Kelley
- Kennedy Krieger Institute, Baltimore Maryland 21205, USA.
| | | |
Collapse
|
27
|
Nowaczyk MJ, Nakamura LM, Eng B, Porter FD, Waye JS. Frequency and ethnic distribution of the common DHCR7 mutation in Smith-Lemli-Opitz syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS 2001; 102:383-6. [PMID: 11503168 DOI: 10.1002/ajmg.1441] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is an inherited multiple malformation syndrome caused by enzymatic deficiency of 3beta-hydroxysterol-Delta(7)-reductase (DHCR7). SLOS is thought to be most common among European Caucasians, with an incidence of 1 in 20,000 to 1 in 30,000 births. To define the carrier rate and ethnic distribution of SLOS, we screened DNA samples from 2,978 unrelated individuals for the most common SLOS mutation (IVS8-1G-->C). Twenty-four heterozygotes of the IVS8-1G-->C mutation were detected in 2,978 individuals of European Caucasian and Black backgrounds. For European Caucasians, the carrier rate for SLOS may be as high as 1 in 30, suggesting an incidence of 1 in 1,700 to 1 in 13,400. This high number is supported by the recent observation of newborn and prenatal incidence of 1 in 22,000 in the Caucasian population. Ours is the first report of the IVS8-1G-->C mutation in persons of African ancestry. Published 2001 Wiley-Liss, Inc.
Collapse
Affiliation(s)
- M J Nowaczyk
- Department of Pathology and Molecular Medicine, McMaster University, 1200 Main Street West, Hamilton, Ontario L8S 4JP, Canada.
| | | | | | | | | |
Collapse
|
28
|
Abstract
Over the past few years, the number of identified inborn errors of cholesterol biosynthesis has increased significantly. The first inborn error of cholesterol biosynthesis to be characterized, in the mid 1980s, was mevalonic aciduria. In 1993, Irons et al. ( 1 ) (M. Irons, E. R. Elias, G. Salen, G. S. Tint, and A. K. Batta, Lancet 341:1414, 1993) reported that Smith-Lemli-Opitz syndrome, a classic autosomal recessive malformation syndrome, was due to an inborn error of cholesterol biosynthesis. This was the first inborn error of postsqualene cholesterol biosynthesis to be identified, and subsequently additional inborn errors of postsqualene cholesterol biosynthesis have been characterized to various extent. To date, eight inborn errors of cholesterol metabolism have been described in human patients or in mutant mice. The enzymatic steps impaired in these inborn errors of metabolism include mevolonate kinase (mevalonic aciduria as well as hyperimmunoglobulinemia D and periodic fever syndrome), squalene synthase (Ss-/- mouse), 3beta-hydroxysteroid Delta14-reductase (hydrops-ectopic calcification-moth-eaten skeletal dysplasia), 3beta-hydroxysteroid dehydrogenase (CHILD syndrome, bare patches mouse, and striated mouse), 3beta-hydroxysteroid Delta8,Delta7-isomerase (X-linked dominant chondrodysplasia punctata type 2, CHILD syndrome, and tattered mouse), 3beta-hydroxysteroid Delta24-reductase (desmosterolosis) and 3beta-hydroxysteroid Delta7-reductase (RSH/Smith-Lemli-Opitz syndrome and Dhcr7-/- mouse). Identification of the genetic and biochemical defects which give rise to these syndromes has provided the first step in understanding the pathophysiological processes which underlie these malformation syndromes.
Collapse
Affiliation(s)
- N A Nwokoro
- Heritable Disorders Branch, National Institutes of Health, Bethesda, Maryland 20892, USA
| | | | | |
Collapse
|
29
|
Lu K, Lee MH, Hazard S, Brooks-Wilson A, Hidaka H, Kojima H, Ose L, Stalenhoef AFH, Mietinnen T, Bjorkhem I, Bruckert E, Pandya A, Brewer, Jr. HB, Salen G, Dean M, Srivastava A, Patel SB. Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively. Am J Hum Genet 2001; 69:278-90. [PMID: 11452359 PMCID: PMC1201544 DOI: 10.1086/321294] [Citation(s) in RCA: 255] [Impact Index Per Article: 11.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2001] [Accepted: 05/24/2001] [Indexed: 11/03/2022] Open
Abstract
Sitosterolemia is a rare autosomal recessive disorder characterized by (a) intestinal hyperabsorption of all sterols, including cholesterol and plant and shellfish sterols, and (b) impaired ability to excrete sterols into bile. Patients with this disease have expanded body pools of cholesterol and very elevated plasma plant-sterol species and frequently develop tendon and tuberous xanthomas, accelerated atherosclerosis, and premature coronary artery disease. In previous studies, we have mapped the STSL locus to human chromosome 2p21. Recently, we reported that a novel member of the ABC-transporter family, named "sterolin-1" and encoded by ABCG5, is mutated in 9 unrelated families with sitosterolemia; in the remaining 25 families, no mutations in sterolin-1 could be identified. We identified another ABC transporter, located <400 bp upstream of sterolin-1, in the opposite orientation. Mutational analyses revealed that this highly homologous protein, termed "sterolin-2" and encoded by ABCG8, is mutated in the remaining pedigrees. Thus, two highly homologous genes, located in a head-to-head configuration on chromosome 2p21, are involved as causes of sitosterolemia. These studies indicate that both sterolin-1 and sterolin-2 are indispensable for the regulation of sterol absorption and excretion. Identification of sterolin-1 and sterolin-2 as critical players in the regulation of dietary-sterol absorption and excretion identifies a new pathway of sterol transport.
Collapse
Affiliation(s)
- Kangmo Lu
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Mi-Hye Lee
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Starr Hazard
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Angela Brooks-Wilson
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Hideki Hidaka
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Hideto Kojima
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Leiv Ose
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Anton F. H. Stalenhoef
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Tatu Mietinnen
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Ingemar Bjorkhem
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Eric Bruckert
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Arti Pandya
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - H. Bryan Brewer, Jr.
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Gerald Salen
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Michael Dean
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Anand Srivastava
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| | - Shailendra B. Patel
- Division of Endocrinology, Diabetes and Medical Genetics, and BioMolecular Computing Resource, Medical University of South Carolina, Charleston; Xenon Genetics Inc., Vancouver; Sanyo Electric Group Health Insurance Association, Osaka; Third Department of Medicine, Shiga University of Medical Science, Otsu, Japan; Lipid Research Clinic, Rikshospitalet, Oslo; Department of Medicine, Division of General Internal Medicine, University Hospital Nijmegen, Nijmegen, The Netherlands; Department of Internal Medicine, Helsinki University Central Hospital, Helsinki; Division of Clinical Chemistry, Karolinska Institutet, Huddinge University, Huddinge, Sweden; Department of Endocrinology, Cardiovascular Disease Prevention, Hôpital Pitié-Salpêtrière, Paris; Department of Human Genetics, Virginia Commonwealth University, Richmond; Molecular Disease Branch, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda; Division of Gasteroenterology, University of Medicine and Dentistry New Jersey, Newark; Laboratory of Genomic Diversity, National Cancer Institute–Frederick, Frederick, MD; and J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, SC
| |
Collapse
|
30
|
Nowaczyk MJ, Waye JS. The Smith-Lemli-Opitz syndrome: a novel metabolic way of understanding developmental biology, embryogenesis, and dysmorphology. Clin Genet 2001; 59:375-86. [PMID: 11453964 DOI: 10.1034/j.1399-0004.2001.590601.x] [Citation(s) in RCA: 44] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The brief history of the Smith-Lemli-Opitz syndrome (SLOS) (MIM 270400) reflects that of latter 20th century dysmorphology and biochemical and molecular genetics: from its first description as a rare but characteristic multiple malformation syndrome known only to a handful of dysmorphologists, to a relatively common Garrodian defect with a complex molecular basis that has captured the attention of researchers and basic scientists from the fields as diverse as embryology, developmental biology, sterol biochemistry, epidemiology, and teratology. The discovery of the underlying biochemical defect - deficiency of 3beta-hydroxysteroid-Delta7-reductase (DHCR7), an enzyme catalyzing the last step of cholesterol biosynthesis, and the resultant generalized cholesterol deficiency - has led to an explosion of knowledge of this biochemical pathway and to a paradigm shift in the recognition of metabolic deficiencies as causes of dysmorphic syndromes. Characterization of the human DHCR7 gene and the identification of mutations in patients with SLOS have revealed a complex picture of molecular heterogeneity and provided insights into the structure and function of DHCR7. SLOS is the first metabolic malformation syndrome with profound effects on the body plan, and its discovery has paved the way to the discovery of a number of other defects of the cholesterol synthetic pathway.
Collapse
Affiliation(s)
- M J Nowaczyk
- Department of Pathology and Molecular Medicine, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario, Canada L8S 4J9.
| | | |
Collapse
|
31
|
Nowaczyk MJ, Heshka T, Eng B, Feigenbaum AJ, Waye JS. DHCR7 genotypes of cousins with Smith-Lemli-Opitz syndrome. AMERICAN JOURNAL OF MEDICAL GENETICS 2001; 100:162-3. [PMID: 11298379 DOI: 10.1002/ajmg.1227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive disorder of cholesterol biosynthesis caused by mutations of the 7-dehydrocholesterol reductase gene (DHCR7). We report on three cousins with SLOS, all of whom were found to be compound heterozygotes for the common splice site mutation IVS8-1G-->C and the missense mutation T289I. DNA analysis of one set of parents demonstrated that the father carried the missense mutation and the mother carried the IVS8-1G-->C mutation. By extension, the two unrelated mothers were both heterozygous for IVS8-1G-->C. This finding supports the notion of a high carrier frequency of the IVS8-1G-->C null mutation in Northern European Caucasians.
Collapse
Affiliation(s)
- M J Nowaczyk
- Department of Pathology and Molecular Medicine, McMaster University, Hamilton, Ontario, Canada.
| | | | | | | | | |
Collapse
|
32
|
BOEHMER ANNEMIEL, NIJMAN RIENJ, LAMMERS BRIGITTEA, DE CONINCK SJEFJ, VAN HEMEL JANO, THEMMEN AXELP, MUREAU MARCA, DE JONG FRANKH, BRINKMANN ALBERTO, NIERMEIJER MARTINUSF, DROP STENVERTL. ETIOLOGICAL STUDIES OF SEVERE OR FAMILIAL HYPOSPADIAS. J Urol 2001. [DOI: 10.1016/s0022-5347(05)66505-6] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Affiliation(s)
- ANNEMIE L.M. BOEHMER
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - RIEN J.M. NIJMAN
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - BRIGITTE A.S. LAMMERS
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - SJEF J.F. DE CONINCK
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - JAN O. VAN HEMEL
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - AXEL P.N. THEMMEN
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - MARC A.M. MUREAU
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - FRANK H. DE JONG
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - ALBERT O. BRINKMANN
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - MARTINUS F. NIERMEIJER
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| | - STENVERT L.S. DROP
- From the Division of Endocrinology, Departments of Pediatrics and Pediatric Urology, Sophia Children’s Hospital, Department of Endocrinology and Reproduction, Erasmus University Rotterdam and Departments of Clinical Genetics, Plastic and Reconstructive Surgery and Internal Medicine III, University Hospital Rotterdam, Rotterdam The Netherlands
| |
Collapse
|
33
|
|
34
|
Abstract
The Smith-Lemli-Opitz syndrome (SLOS) is an autosomal recessive metabolic disorder characterized by variable congenital malformations, facial dysmorphism, and mental retardation. Mutations in the DHCR7 gene have been identified in SLOS patients. This gene encodes for the enzyme Delta7-sterol reductase which catalyses the last step of cholesterol biosynthesis. Among the 73 different mutations observed so far, including 10 novel mutations reported in this review, the majority are missense mutations (65) which cluster in three domains of the protein: in the transmembrane domain (TM mutations), in the fourth cytoplasmic loop (4L mutations), and at the C-terminus (CT mutations). Two nonsense mutations, one splice site mutation, two single nucleotide insertions, and three deletions which likely all represent null mutations were also described. Expression studies have demonstrated a decreased protein stability for all analyzed missense mutations. By comparing clinical severity scores, biochemical data, and mutations in SLOS patients a genotype-phenotype correlation has been established. The null and 4L mutations are associated with a severe clinical phenotype, and TM and CT mutations are associated with a mild clinical phenotype. DHCR7 mutational spectra in SLOS patients of British, German, Italian, and Polish origin demonstrate significant geographic frequency differences of common DHCR7 mutations.
Collapse
Affiliation(s)
- M Witsch-Baumgartner
- Institute of Medical Biology and Human Genetics, University of Innsbruck, Innsbruck, Austria
| | | | | |
Collapse
|
35
|
Lee MH, Lu K, Hazard S, Yu H, Shulenin S, Hidaka H, Kojima H, Allikmets R, Sakuma N, Pegoraro R, Srivastava AK, Salen G, Dean M, Patel SB. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat Genet 2001; 27:79-83. [PMID: 11138003 PMCID: PMC1350991 DOI: 10.1038/83799] [Citation(s) in RCA: 444] [Impact Index Per Article: 19.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
The molecular mechanisms regulating the amount of dietary cholesterol retained in the body, as well as the body's ability to exclude selectively other dietary sterols, are poorly understood. An average western diet will contain about 250-500 mg of dietary cholesterol and about 200-400 mg of non-cholesterol sterols. About 50-60% of the dietary cholesterol is absorbed and retained by the normal human body, but less than 1% of the non-cholesterol sterols are retained. Thus, there exists a subtle mechanism that allows the body to distinguish between cholesterol and non-cholesterol sterols. In sitosterolemia, a rare autosomal recessive disorder, affected individuals hyperabsorb not only cholesterol but also all other sterols, including plant and shellfish sterols from the intestine. The major plant sterol species is sitosterol; hence the name of the disorder. Consequently, patients with this disease have very high levels of plant sterols in the plasma and develop tendon and tuberous xanthomas, accelerated atherosclerosis, and premature coronary artery disease. We previously mapped the STSL locus to human chromosome 2p21 and further localized it to a region of less than 2 cM bounded by markers D2S2294 and D2S2291 (M.-H.L. et al., manuscript submitted). We now report that a new member of the ABC transporter family, ABCG5, is mutant in nine unrelated sitosterolemia patients.
Collapse
Affiliation(s)
- Mi-Hye Lee
- Division of Endocrinology, Diabetes and Medical Genetics, and
| | - Kangmo Lu
- Division of Endocrinology, Diabetes and Medical Genetics, and
| | - Star Hazard
- BioMolecular Computing Resource, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Hongwei Yu
- Division of Endocrinology, Diabetes and Medical Genetics, and
| | - Sergey Shulenin
- Laboratory of Genomic Diversity, National Cancer Institute-FCRDC, Frederick, Maryland, USA
| | - Hideki Hidaka
- Sanyo Electric Group Health Insurance Association, Kaneshita-cho, 2-11-10 Moriguchi, Osaka, Japan
| | - Hideto Kojima
- Third Department of Medicine, Shiga University of Medical Science, Seta, Otsu, Shiga 520-21, Japan
| | - Rando Allikmets
- Departments of Opthalmology and Pathology, College of Physicians and Surgeons, Columbia University, New York, New York, USA
| | - Nagahiko Sakuma
- Third Department of Medicine, Nagoya City University, Nagoya 467-861, Japan
| | - Rosemary Pegoraro
- Department of Chemical Pathology, Nelson R. Mandela School of Medicine, University of Natal, Congella 4013, Durban, South Africa
| | - Anand K. Srivastava
- J. C. Self Research Institute of Human Genetics, Greenwood Genetics Center, Greenwood, South Carolina, USA
| | - Gerald Salen
- Division of Gastroenterology, University of Medicine and Dentistry New Jersey, Newark, New Jersey, USA
| | - Michael Dean
- BioMolecular Computing Resource, Medical University of South Carolina, Charleston, South Carolina, USA
| | - Shailendra B. Patel
- Division of Endocrinology, Diabetes and Medical Genetics, and
- Correspondence should be addressed to S.B.P. (e-mail:
)
| |
Collapse
|
36
|
Porter FD. RSH/Smith-Lemli-Opitz syndrome: a multiple congenital anomaly/mental retardation syndrome due to an inborn error of cholesterol biosynthesis. Mol Genet Metab 2000; 71:163-74. [PMID: 11001807 DOI: 10.1006/mgme.2000.3069] [Citation(s) in RCA: 88] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The RSH/Smith-Lemli-Opitz syndrome (RSH/SLOS) is an autosomal recessive multiple congenital anomaly/mental retardation syndrome caused by an inborn error of cholesterol biosynthesis. The RSH/SLOS phenotypic spectrum is broad; however, typical features include microcephaly, ptosis, a small upturned nose, micrognathia, postaxial polydactaly, second and third toe syndactaly, genital anomalies, growth failure, and mental retardation. RSH/SLOS is due to a deficiency of the 3beta-hydroxysterol Delta(7)-reductase, which catalyzes the reduction of 7-dehydrocholesterol (7-DHC) to cholesterol. This inborn error of cholesterol biosynthesis results in elevated serum and tissue 7-DHC levels. The 3beta-hydroxysterol Delta(7)-reductase gene (DHCR7) maps to chromosome 11q12-13, and to date 66 different mutations of this gene have been identified in RSH/SLOS patients. Identification of the biochemical basis of RSH/SLOS has led to development of therapeutic regimens based on dietary cholesterol supplementation and has increased our understanding of the role cholesterol plays during embryonic development.
Collapse
Affiliation(s)
- F D Porter
- Heritable Disorders Branch, National Institutes of Health, Bethesda, Maryland 20892-1830, USA
| |
Collapse
|